Tiotropium versus placebo for chronic obstructive pulmonary disease
about
Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary diseaseLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthmaLong-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary diseaseLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthmaLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta 2 -agonists (LABA) for adults with asthmaLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthmaLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthmaLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS for adults with asthmaCombination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary diseaseA rational approach to single, dual and triple therapy in COPDClinical potential of aclidinium bromide in chronic obstructive pulmonary diseaseLong-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerationsPharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewInterpreting patient-reported outcomes from clinical trials in COPD: a discussionA systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study.Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions.Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trialsThe Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research.Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trialChange in health status in COPD: a seven-year follow-up cohort study.Persistent disabling breathlessness in chronic obstructive pulmonary disease.Inhaled treatment for chronic obstructive pulmonary disease: what's new and how does it fit?Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular riskThis patient is not breathing properly: is this COPD, heart failure, or neither?Tiotropium bromide exerts anti-inflammatory effects during resistive breathing, an experimental model of severe airway obstruction.Paradigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular disease.Tiotropium for the Treatment of Asthma: Patient Selection and Perspectives.
P2860
Q24186304-CEA98170-2ACC-4103-9A79-B9684C2F9E08Q24186370-6DE1FB19-0343-4006-AF0D-C08D1C27821CQ24186411-FB15AB4F-2EB4-4E24-A08D-5E04B9298FC3Q24187031-ED2880A9-252D-48FF-9E39-0AF23198CA34Q24187322-9957EBFC-36D0-484C-AE0E-CCBDC09D098DQ24187595-90A4399D-1D13-4779-A622-EAE232D1D2C9Q24187757-6C2ABB24-FDC2-4A8C-80D1-2CE0F76D64EDQ24188213-25BF8C55-E43D-4BA1-BD41-03C803B09D15Q26471530-691260CA-9A5C-403D-AE92-4127E514E76EQ26776477-7C92BBFA-0A89-47BA-82DF-CC9AF9697A9DQ27023223-ECD48E2B-EC14-4810-B3EE-6ABA30ABF828Q28067579-C6D6409A-E1DA-461E-8769-9E0894EA4514Q28070274-C4B512E9-D6A1-4009-B4A4-84D48E24E438Q28072901-13E86186-C073-4CAC-8A34-DA1060227729Q30820402-C37A0280-66BD-4F96-A1AB-1BB05981B0DCQ33698659-5380462D-0AD7-4C74-9A81-BA4EF7ED1974Q34628637-4A56B8A3-9023-4714-B669-23CA2536493DQ35584046-FFF5BCAA-B093-49AB-8C88-A24ED20975E3Q35914833-27457723-3EC9-48B8-B21A-0C64473EBB84Q36251424-4A6A8F3D-50EB-4BB0-81E8-95ACEB97F928Q36456873-FF719430-CA37-4AA1-9E4C-9A2E489B26C3Q37353892-0AF33D1D-D03D-4640-97F3-D8BF02289ED5Q37412885-A951B50C-F900-403F-AC7B-653498154589Q38630770-DBC6BBA4-F3BE-4777-9DBF-E7246D4FBC98Q38833618-678B3E00-F9F7-4F59-B647-B8DED473800DQ39232408-6BC1F37B-3C85-4354-8365-EA2D79802396Q41276617-CC6D8C7A-6EFF-4C03-BE29-1846D3AB9E7FQ46165199-CAC56AB0-024F-48DE-BBCC-8BE4890E04E6Q55131618-319C431E-78B5-4324-A35F-AA2729C3F23A
P2860
Tiotropium versus placebo for chronic obstructive pulmonary disease
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tiotropium versus placebo for chronic obstructive pulmonary disease
@ast
Tiotropium versus placebo for chronic obstructive pulmonary disease
@en
Tiotropium versus placebo for chronic obstructive pulmonary disease
@en-gb
Tiotropium versus placebo for chronic obstructive pulmonary disease
@nl
type
label
Tiotropium versus placebo for chronic obstructive pulmonary disease
@ast
Tiotropium versus placebo for chronic obstructive pulmonary disease
@en
Tiotropium versus placebo for chronic obstructive pulmonary disease
@en-gb
Tiotropium versus placebo for chronic obstructive pulmonary disease
@nl
prefLabel
Tiotropium versus placebo for chronic obstructive pulmonary disease
@ast
Tiotropium versus placebo for chronic obstructive pulmonary disease
@en
Tiotropium versus placebo for chronic obstructive pulmonary disease
@en-gb
Tiotropium versus placebo for chronic obstructive pulmonary disease
@nl
P2860
P3181
P1476
Tiotropium versus placebo for chronic obstructive pulmonary disease
@en
P2093
Charlotta Karner
Jimmy Chong
P2860
P304
P3181
P356
10.1002/14651858.CD009285.PUB3
P407
P577
2014-07-21T00:00:00Z